< Back to search
Filter
1
Active & Responsive

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

for
Relapsing Multiple Sclerosis,
Location: Worcester MA, New York NY, Philadelphia PA, Richmond VA,
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Sex: All

Age: 18 - 55

Code: NCT04047628

Phase3, Recruiting
Active & Responsive

Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis

for
Multiple Sclerosis,
Location: Chicago IL
Sponsor: Northwestern University

Sex: All

Age: 18 - 70

Code: NCT07225361

Recruiting
Active & Responsive

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

for
Multiple Sclerosis (MS) - Relapsing-remitting
Location: Atlanta GA
Sponsor: Georgia State University

Sex: All

Age: 18 - 55

Code: NCT06629428

Early_phase1, Recruiting
Active & Responsive

Home Based Functional Balance Intervention for Multiple Sclerosis

for
Multiple Sclerosis,
Location: Chicago IL
Sponsor: University of Illinois at Chicago

Sex: All

Age: 40 - 70+

Code: NCT07355387

Recruiting
Active & Responsive

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

for
Relapsed/Refractory Multiple Myeloma
Location: New York NY, Hackensack NJ, Richmond VA, Durham NC,
Sponsor: Caribou Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT05722418

Phase1, Recruiting

Interested in new relapsing multiple sclerosis trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & ResponsiveNew

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

for
Relapsed or Refractory Multiple Myeloma
Location: Duarte CA
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07681596

Phase1, Phase2, Recruiting
Active & Responsive

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

for
Relapsed Refractory Multiple Myeloma
Location: New Haven CT, New York NY, Montreal, Winston-Salem NC,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07391657

Phase3, Recruiting
Active & Responsive

A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

for
Multiple Myeloma in Relapse, Myeloma Multiple,
Location: Boston MA, Hackensack NJ, Tampa FL, Atlanta GA,
Sponsor: Kelonia Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07075185

Phase1, Recruiting
Active & Responsive

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

for
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Location: New York NY, Chapel Hill NC, Jacksonville FL,
Sponsor: C4 Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07284758

Phase2, Recruiting
Active & Responsive

HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM

for
Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Location: Durham NC
Sponsor: Duke University

Sex: All

Age: 18+

Code: NCT06822972

Phase2, Recruiting

Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod

for
Relapsing Multiple Sclerosis
Location: Cleveland OH, Aurora CO, Las Vegas NV
Sponsor: University of Colorado, Denver

Sex: All

Age: 18+

Code: NCT06529406

Recruiting

A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk

for
Relapsing Multiple Sclerosis
Location: Boston MA, Wilmington NC, Smyrna GA, Nashville TN,
Sponsor: TG Therapeutics, Inc.

Sex: Female

Age: 18+

Code: NCT06143514

Recruiting

Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab

for
Relapsing Multiple Sclerosis
Location: Boston MA, Foxborough MA, Wellesley MA,
Sponsor: TG Therapeutics, Inc.

Sex: All

Age: 18 - 65

Code: NCT05877963

Phase3, Recruiting

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

for
Relapsing Multiple Sclerosis
Location: Foxborough MA, Burlington MA, Levis, Teaneck NJ,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 40 - 70

Code: NCT06846281

Phase3, Recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

for
Relapsing Multiple Sclerosis, Multiple Sclerosis
Location: Boston MA, Burlington MA, Norfolk MA, Hartford CT,
Sponsor: TG Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06433752

Recruiting

Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis

for
Multiple Sclerosis, Relapsing-Remitting
Location: Tampa FL, Louisville KY, Chicago IL, Milwaukee WI,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 10 - 17

Code: NCT06408259

Phase3, Recruiting

Intermittent Hypoxia in Persons With Multiple Sclerosis

for
Multiple Sclerosis, Multiple Sclerosis-Relapsing-Remitting,
Location: Chicago IL
Sponsor: Shirley Ryan AbilityLab

Sex: All

Age: 18 - 70+

Code: NCT06276634

Recruiting

Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation

for
Multiple Sclerosis, Relapsing-Remitting
Location: Richardson TX
Sponsor: The University of Texas at Dallas

Sex: All

Age: 18 - 65

Code: NCT05958381

Recruiting

Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis

for
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting,
Location: Cleveland OH
Sponsor: Cionic, Inc.

Sex: All

Age: 22 - 70+

Code: NCT05964829

Recruiting

The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study

for
Relapsing Remitting Multiple Sclerosis
Location: Baltimore MD, Morgantown WV, Atlanta GA, Milwaukee WI,
Sponsor: SetPoint Medical Corporation

Sex: All

Age: 22 - 60

Code: NCT06796504

Recruiting